Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease

Hepatology

Volumn 55, Issue 6, 2012, Pages 1809-1819

  Reddy, Srinevas K ^a   Steel, Jennifer L ^a   Chen, Hui Wei ^a   Demateo, David J ^a   Cardinal, Jon ^a   Behari, Jaideep ^a   Humar, Abhinav ^a   Marsh, J Wallis ^a   Geller, David A ^a   Tsung, Allan ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHLOROTRIANISENE; CREATININE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALCOHOL LIVER DISEASE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DISEASE SEVERITY; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; LIVER RESECTION; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; FATTY LIVER; FEMALE; HEPATITIS C; HUMANS; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84861647264     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25536     Document Type: Article

References (52)

1. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. HEPATOLOGY 2010; 51: 1820-1832.
2. Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 2009; 13: 631-647.
3. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting. J Clin Oncol 2010; 28: 3994-4005.
4. Davilla JA, Morgan RO, Shaib Y, McGlynn KA, El-Seraq HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 24: 533-539.
5. Bataller R, Rombouts K, Altamirano J, Marra F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2011; 25: 231-244.
6. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009; 115: 5651-5661.
7. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
8. Hashimoto E, Tokushige K. Prevalence, gender, ethinic variations, and prognosis of NASH. J Gastroenterol 2011; 46(Suppl 1]: 63-69.
9. Pascale A, Pais R, Ratziu V. An overview of nonalcoholic steatohepatitis: past, present, and future directions. J Gastrointest Liver Dis 2010; 19: 415-423.
10. Younossi AM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1998 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.e1; quiz, e60.
11. Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M; Japan Etiology of Liver Cirrhosis Study Group. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2010; 45: 86-94.
12. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44(Suppl XIX): 89-95.
13. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-1216.
14. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-1523.
15. Aly FZ, Kleiner DE. Update on fatty liver disease and steatohepatitis. Adv Anat Pathol 2011; 18: 294-300.
16. Argo CK, Northup PG, Al-Osaimi AMS, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-379.
17. Berman, K, Tandra S, Vuppalanch R, Ghabril M, Sandrasegaran K, Nguyen J, et al. Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol 2011; 106: 899-906.
18. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. HEPATOLOGY 2006; 43: 682-689.
19. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253.
20. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. HEPATOLOGY 2003; 38: 420-427.
21. Welzel TM, Graubard BI, Zeuzem S, El-Sereg HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-medicare database. Hepatology 2011; 54: 463-471.
22. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010; 29: 1303-1307.
23. Ascha M, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. HEPATOLOGY 2010; 51: 1972-1978.
24. Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Shiratori K. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma cause by chronic hepatitis C. J Gastroenterol 2010; 45: 960-967.
25. Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, et al. Hepatocellular carcinoma arising from non-cirrhotic alcoholic steatohepatitis. J Gastroenterol 2009; 44: 1190-1194.
26. Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 2009; 20: 353-357.
27. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-380.
28. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. HEPATOLOGY 2002; 35: 1485-1493.
29. Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, et al. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 2007; 102: 1939-1946.
30. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.
31. Smoot RL, Nagorney DM, Chandan VS, Que FG, Schleck CD, Harmsen WS, Kendrick ML. Resection of hepatocellular carcinoma in patients without cirrhosis. Br J Surg 2011; 98: 697-703.
32. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 428-433.
33. Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2011 May 4. doi:10.1002/ijc.26165.
34. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. HEPATOLOGY 2011; 54: 344-353.
35. Eckel RH, Alberti KGMM, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010; 375: 181-183.
36. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
37. Sobin LH, Gospodarowicz MK, Wittekind C. (eds.). TNM classification of malignant tumors, 7th ed. Oxford, UK: Wiley-Blackwell; 2009.
38. Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, Tokushige K, Shiratori K. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J Gastroenterol 2004; 39: 1215-1218.
39. Yang JD, Harmsen WS, Slettedahl SW, Chaiterrakij R, Enders FT, Therneau TM, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 2011; 9: 617-623.e1.
40. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. HEPATOLOGY 2009; 49: 851-859.
41. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory, and histological associations in adults with nonalcoholic fatty liver disease. HEPATOLOGY 2010; 52: 913-924.
42. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. HEPATOLOGY 2011; 53: 810-820.
43. Brunt EM. Non-alcoholic fatty liver disease: what's new under the microscope? Gut 2011; 60: 1152-1158.
44. Wu TH, Yu MC, Chan KM, Lee CF, Chen TC, Chang HC, et al. Prognostic effect of steatosis on hepatocellular carcinoma patients after liver resection. Eur J Surg Oncol 2011; 37: 618-622.
45. Kobayashi T, Itamoto T, Tashiro H, Amano H, Oshita A, Tanimoto Y, et al. Tumor-related factors do not influence the prognosis of solitary hepatocellular carcinoma after partial hepatectomy. J Hepatobiliary Pancreat Surg 2011; 18: 689-699.
46. Billimoria MM, Lauwers GY, Doherty DA, Nagorney DM, Belghiti J, Do KA, et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001; 136: 528-535.
47. Salomao M, Yu WM, Brown RS, Jr., Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histologic variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010; 34: 1630-1636.
48. Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, Di Bisceglie AM. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003; 16: 49-56.
49. Bedosa P, Moucari R, Chelbi E, Asselah T, Paradis V, Vidaud M, et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. HEPATOLOGY 2007; 46: 380-387.
50. Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch Surg 2011; 458: 511-523.
51. Leite NC, Villela-Nogueira CA, Pannain VLN, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int 2011; 31: 700-706.
52. Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. HEPATOLOGY 2009; 49: 809-820.